drugset / Trial / NCT00946335
ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors
NaSingle-groupOpen-labelTreatment
Summary
This phase I trial is studying the side effects and best dose of ABT-888 when given in combination with temozolomide in treating young patients with recurrent or refractory CNS tumors. ABT-888 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving ABT-888 together with temozolomide may kill more tumor cells.
Timeline
- Start
- 2009-07
- Primary completion
- 2011-10
- Completion
- 2014-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Temozolomide | Small molecule | — | Oral |
| Subject | Veliparib | Small molecule | — | Oral |
Indications
atypical teratoid rhabdoid tumor
benign meningioma
childhood brain stem glioma
childhood central nervous system germ cell tumor
childhood cerebellar astrocytic neoplasm
childhood cerebral astrocytoma
childhood choroid plexus neoplasm
childhood medulloblastoma
childhood oligodendroglioma
childhood spinal cord tumor
craniopharyngioma
ependymoblastoma
grade II meningioma
grade III meningioma
medulloepithelioma
mixed glioma
optic pathway glioma
pediatric infratentorial ependymoma
pediatric supratentorial ependymoma
pineoblastoma
subependymal giant cell astrocytoma
supratentorial primitive neuroectodermal tumor